A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center phase 1b study to evaluate the safety and efficacy of
Sirolimus for injection (albumin-bound) in patients with malignant solid tumors with TSC1 or
TSC2 genetic alterations.